Drug Profile


Alternative Names: Inegy; MK-0653A; Simvastatin/ezetimibe; Vytorin; Zetia™/Zocor®; Zintrepid; Zocor®/Zetia™

Latest Information Update: 25 Mar 2017

Price : $50

At a glance

  • Originator Merck/Schering-Plough Pharmaceuticals
  • Class Antihyperlipidaemics; Azetidines; Naphthalenes; Small molecules
  • Mechanism of Action Cholesterol absorption inhibitors; HMG-CoA reductase inhibitors
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

  • On Fast track

    Fast track status is assigned by the US FDA so therapies with the potential to address unmet needs can move faster through development.

  • New Molecular Entity No

Highest Development Phases

  • Marketed Acute coronary syndromes; Hypercholesterolaemia; Hyperlipidaemia
  • Discontinued Aortic valve stenosis

Most Recent Events

  • 28 Feb 2017 Merck has patent protection for ezetimibe/simvastatin (Vytorin®) in Europe and Japan (Merck Annual report 2016)
  • 15 Feb 2016 Merck receives complete response letter from the FDA for ezetimibe/simvastatin in Acute coronary syndromes
  • 14 Dec 2015 Preregistration for Acute coronary syndromes in USA (PO) before December 2015
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top